SEC Form 4 · accession 0001193125-26-389564
Aardvark Therapeutics, Inc. · AARD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nelson Sun
Officer — See Remarks
Period of report
Sep 10, 2026
Accepted (ET)
Sep 11, 2026 · 8:14 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001774857
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.00001 per shareF2,F3 | Sep 10, 2026 | S | 14,754 | $5.0006 | D | 97,475 | D | |
| Common Stock, par value $0.00001 per share | Sep 11, 2026 | S | 62,000 | $5.1803 | D | 35,475 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026.
- F2The price reported in Column 4 reflects the weighted-average sales price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.0007, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F3Includes 3,745 shares of common stock acquired pursuant to the Issuer's 2025 Employee Stock Purchase Plan on May 22, 2026.
Remarks
Chief Financial & Operating Officer